AML

Question 1

Incidence of AML increases logarithmically with age except

Answer 1

APL
(incidence of APL is constant over human life span)

Question 2

2 most common symptoms and signs of marrow necrosis

Answer 2

bone pain and fever

Question 3

Cytogenetic abnormality in APL that confers resistant to retinoid therapy

Answer 3

PLZF-RARa fusion
T (11;17)

Question 4

Prevalent variant of AML that develops in patients with Down syndrome

Answer 4

Acute Megakayoblastic Leukemia

Question 5

True of False:
Most cases of Acute basophilic leukemia evolve from the chronic phase of CML

Answer 5

True

Question 6

Cluster of differentiation specific for basophilic differentiation

Answer 6

CD9 and CD25

Question 7

Complete remission in AML is defined as

Answer 7

<2% blasts in the marrow
neutrophil count >1x 109/L
platelet count >100 x 109/L

Question 8

Anthracycline that reduced the development of drug resistance

Answer 8

Idarubicin

Question 9

A multitargeted kinase inhibitor use in AML patients with FLT3 ITD or TKD point mutations

Answer 9

Midostaurin

Question 10

a humanized anti-CD33 monoclonal antibody conjugated to calicheamin

Answer 10

Gemtuzumab ozogamicin

Question 11

main toxicity of Gemtuzumab ozogamicin

Answer 11

prolonged thrombocytopenia

Question 12

a liposomal preparation of daunorubicin and cytarabine used for secondary AML or MDS-related cytogenetics

Answer 12

Liposomal CPX-351

Question 13

Recommended phase 2 dose of venetoclax in combination with HMA

Answer 13

400mg/day

Question 14

hedgehog pathway inhibitor approved by FDA for oral administration in combination with LDAC

Answer 14

Glasdegib

Question 15

oral small molecule inhibitor of IDH2

Answer 15

Enasidenib

Question 16

oral inhibitor of IDH1

Answer 16

Ivosidenib

Question 17

most serious complications of hyperleukocytosis

Answer 17

intracranial hemorrhage
pulmonary insufficiency

Question 18

Leukapheresis can decrease blast count by approximately how many percent?

Answer 18

30%

Question 19

True or False
In patients with CNS leukemia, prophylactic intrathecal chemotherapy is not recommended if high dose cytarabine is used for consolidation

Answer 19

True

Question 20

duration of Cytarabine infusion that would decrease the likelihood of severe cerebellar toxicity

Answer 20

1 hour

Question 21

Upper age limit for alloHSCT in AML

Answer 21

no strict upper age limit

Question 22

2 major complications of DLI

Answer 22

GVHD
marrow aplasia

Question 23

True or False
Extramedullary sites of relapse are more common after transplantation

Answer 23

True

Question 24

CDK6 inhibitor with activity in MLL-rearranged leukemias

Answer 24

Palbociclib

Question 25

CDK9 inhibitor MCL-1 inhibitor

Answer 25

Alvodicib

Question 26

oral iron chelator that inhibits CD34+CD38- cells through inhibition of NFkb and reactive oxygen species

Answer 26

Deferasirox

Question 27

True or False Treatment related APL and de novo APL are treated similarly

Answer 27

True

Question 28

ATRA alone can induce remission in how many percentage of patients

Answer 28

80%

Question 29

leukemic promyelocytes disappear from blood after ATRA after how many weeks

Answer 29

2-4 weeks

Question 30

a rapid increase in total blood leukocyte count in the first several weeks of therapy with ATRA

Answer 30

Differentiation syndrome

Question 31

key feature of differentiation syndrome

Answer 31

respiratory distress

Question 32

True or False. Differentiation syndrome can occur in maintenance therapy

Answer 32

False

Question 33

Preferred anthracycline in pregnant women

Answer 33

Doxorubicin (due to low transplacental transfer)

Question 34

spontaneous remissions can occur in pediatric AML with this cytogenetics

Answer 34

t (8;16) (p11;23)

Question 35

2 most important predictors of treatment related mortality

Answer 35

Age Performance status

Question 36

2 most compelling determinants of poor outcome

Answer 36

Older age Less favorable cytogenetics

Question 37

True or False. Marrow examination are not needed in the majority of AML patients in first complete remission

Answer 37

True